Please login to the form below

Not currently logged in

Novartis profits up by almost a third

Second quarter profit for Novartis increased by 29 per cent from 2010, with major launches and approvals overcoming sales lost to generic competition

Second quarter profit for Novartis increased by 29 per cent from 2010, with income for the 2011 period rising to $3.56bn. At constant currencies the increase was similarly strong at 31 per cent.

Income was buoyed by a formidable sales performance, with net sales rising by 27 per cent from $11.72bn in 2010 to $14.91bn for Q2 2011.

Recently launched products, including Gilenya (fingolimod) for multiple sclerosis (MS), accounted for 28 per cent of pharmaceutical sales, bringing in $2.3bn. Gilenya made $79m during the period.

Products that performed particularly well included wet age-related macular degeneration treatment, Lucentis (ranibizumab), with sales increasing by 44 per cent to $541m following approval in the EU.

Further market approvals for leukaemia treatment Tasigna (nilotinib) saw the drug achieve significant revenue growth of 91 per cent, making $170m.

Gleevic/Glivec (imatinib) and Diovan (valsartan) were the company's biggest sellers, making over $1bn each, although Diovan's sales are due to be affected by the launch of generic competition.

Sales were also helped by Novartis' acquisition of Alcon in August 2010, with the eye-care specialists contributing $2.6bn of net sales in the second quarter.

2Excellent execution behind a sound strategy resulted in another successful quarter for Novartis," commented Joseph Jimenez, CEO of the company. "We further demonstrated the success of our R&D strategy with four major approvals and two filings in the second quarter."

Company performance for the first half of the year was also positive, with net sales up 21 per cent to $28.95bn and net profit up 14 per cent to $6.94bn.

19th July 2011


Featured jobs

Subscribe to our email news alerts


Add my company

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...